Recombinant Mouse Epidermal Growth Factor/EGF (C-6His)

Cat.No.: CH28

Recombinant Mouse EGF (C-6His)
Recombinant Mouse epidermal growth factor is produced by our E.coli expression system and the target gene encoding Asn977-Arg1029 is expressed with a 6His tag at the C-terminus.
Accession #:P01132
Known as:Pro-epidermal growth factor; Epidermal growth factor;EGF
Lyophilized from a 0.2 μm filtered solution of 20mM Tris,150mM NaCl,PH8.0.
Quality Control
Purity:Greater than 95% as determined by reducing SDS-PAGE.
BioActivity:Measured in a cell proliferation assay using BALB/c 3T3 cells.The ED50 for this effect is 0.15-1.5 ng/ml.
Endotoxin:Less than 0.1 ng/?g (
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
EGF is a single-pass type I membrane protein,containing 8 LDL-receptor class B repeats and 9 EGF-like domains. EGF results in cellular proliferation, differentiation, and survival.EGF is a low-molecular-weight polypeptide first purified from the mouse submandibular gland, but since then found in many human tissues including submandibular gland, parotid gland. Salivary EGF, which seems also regulated by dietary inorganic iodine, also plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents.
Use of peptides that block metadherin-SND1 interaction as treatment for cancer Kang Yibin, et al. (THE TRUSTEES OF PRINCETON UNIVERSITY patent:10357539 2019)+
The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.

Send Message